Stoke Therapeutics (STOK) Change in Acquisitions & Divestments (2022 - 2026)

Stoke Therapeutics' Change in Acquisitions & Divestments history runs 5 years deep, the most recent figure standing at $60.9 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments rose 85.67% year-over-year to $60.9 million; the TTM figure through Mar 2026 stood at $164.7 million (up 98.89% YoY), while the FY2025 annual figure was $136.6 million, up 127.63% from the prior year.
• Change in Acquisitions & Divestments was $60.9 million for Q1 2026 at Stoke Therapeutics, up from $37.4 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $79.0 million in Q3 2022 to a low of $9.0 million in Q1 2022.
• Historically, Change in Acquisitions & Divestments has averaged $32.8 million across 5 years, with a median of $31.4 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Change in Acquisitions & Divestments surged 491.67% in 2023, then sank 81.22% in 2024.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $18.0 million in 2022, then retreated by 16.8% to $15.0 million in 2023, then soared by 100.0% to $30.0 million in 2024, then grew by 24.66% to $37.4 million in 2025, then jumped by 62.84% to $60.9 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $60.9 million (Q1 2026), $37.4 million (Q4 2025), and $33.2 million (Q3 2025), per Business Quant data.